ENPP3

ENPP3

ENPP3 詳細

Molecule Name
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3
分子の別称
ENPP3,CD203c,NPP3,E-NPP3,PD-Ibeta,NPPase,PDNP3
Drug Development Progress
治験薬の数4
市販薬剤の数0
研究&開発段階Phase 1 Clinical
ターゲットの別称
EC:3.1.4.1,E-NPP 3,PD-Ibeta,NPPase,CD203c,PDNP3,Phosphodiesterase I/nucleotide pyrophosphatase 3,Nucleotide diphosphatase,ENPP3,DJ914N13.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),Phosphodiesterase-I Beta,Phosphodiesterase I Beta,CD203c Antigen,Gp130RB13-6,NPP3,B10,Ectonucleotide pyrophosphatase/phosphodiesterase family member 3,Ectonucleotide Pyrophosphatase/Phosphodiesterase 3,DJ1005H11.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),EC:3.6.1.9
バックグランド
The human NPP family contains seven members which can be classified into two groups according to their substrate preferences. The first class comprises the nucleotide-degrading proteins NPP1, 3 and 4. NPP3 (CD203c, ENPP3) is expressed in multiple organs, including on epithelial and mucosal surfaces, and notably on basophils and mast cells. Activation of basophils by antigen-bound IgE leads to release of inflammatory mediators and rapid upregulation of NPP3 to the cell surface. This protein is in fact a common marker for diagnosing allergen sensitivity with patient basophils by flow cytometry. Basophils and mast cells mediate the response to certain pathogens, as well as acute and chronic allergic reactions. Following activation, these cells release ATP, which further stimulates them in an autocrine manner. NPP3 upregulation serves to degrade ATP and suppress chronic allergic inflammation (but not the acute response).

ENPP3 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
XmAb-819XmAb-819Phase 1 ClinicalXencor Inc
Carcinoma, Renal Cell; Kidney Neoplasms
詳細
JNJ-89862175JNJ-89862175Phase 1 ClinicalJanssen Research & Development Llc
Solid tumours
詳細
ALY-301ALY-301; GTX-B001Phase 1 ClinicalAlys Pharmaceuticals Inc
Chronic Urticaria; Symptomatic Dermographism; Urticaria
詳細
JNJ-87890387JNJ-87890387Phase 1 ClinicalJanssen Research & Development Llc
Neoplasms; Solid tumours
詳細